Back to top
more

Teva Pharmaceutical Industries (TEVA)

(Real Time Quote from BATS)

$16.35 USD

16.35
8,622,609

+0.34 (2.12%)

Updated Aug 7, 2025 02:46 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value F Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 33% (164 out of 246)

Industry: Medical - Generic Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Mylan Suffers a Blow as Teva Gets FDA Nod for EpiPen Generic

by Zacks Equity Research

Mylan (MYL) suffers another setback as Teva wins the FDA approval of first generic version of EpiPen and EpiPen Jr (epinephrine) auto-injector for the emergency treatment of allergic reactions.

    Zacks Equity Research

    Teva Gets FDA Nod for First Generic Version of Mylan's EpiPen

    by Zacks Equity Research

    Teva (TEVA) gains FDA approval for the first generic version of Mylan's (MYL) popular EpiPen (epinephrine) auto-injector for severe allergy treatment.

      Zacks Equity Research

      Regeneron, Teva Announce Positive Data on Osteoarthritis Drug

      by Zacks Equity Research

      Regeneron (REGN) along with partner Teva announces positive top-line results from a late-stage candidate on fasinumab in patients with chronic pain from osteoarthritis of the knee or hip.

        Benjamin Rains headshot

        Invest Like Buffett & Berkshire With These Top Stock Picks

        by Benjamin Rains

        Warren Buffett has for years been looked at as an investment icon, while maintaining a relatively simple mantra. Buffett and Berkshire Hathaway (BRK.B) have long tried to invest in companies that both the Oracle of Omaha and the conglomerate understand. This sounds easy enough, but what are some of Buffett's most recent investments?

          Zacks Equity Research

          Here's Why Lilly (LLY) Stock is Up 15% Since Q2 Earnings

          by Zacks Equity Research

          Eli Lilly's (LLY) stock is up 15% since announcement of earnings in July. Let us have a look at the reasons for the same.

            Zacks Equity Research

            BioDelivery (BDSI) Q2 Loss Narrows, Sales Miss, Shares Down

            by Zacks Equity Research

            BioDelivery Sciences (BDSI) reports narrower-than-expected loss in Q2. Sales marginally miss the consensus mark.

              Zacks Equity Research

              Momenta (MNTA) Earnings and Revenues Lag Estimates in Q2

              by Zacks Equity Research

              Momenta (MNTA) reports wider-than-expected Q2 loss. Sales miss estimates too. The focus now is on the outcome of the ongoing strategic review including a possible sale of the biosimilar business.

                Zacks Equity Research

                TEVA vs. TLGT: Which Stock Is the Better Value Option?

                by Zacks Equity Research

                TEVA vs. TLGT: Which Stock Is the Better Value Option?

                  Zacks Equity Research

                  Mylan (MYL) Q2 Earnings: Is a Disappointment in the Cards?

                  by Zacks Equity Research

                  Investors will focus on the performance of EpiPen, newly launched biosimilars along with other updates from Mylan's (MYL) pipeline, when it reports Q2 results (scheduled for Aug 8).

                    Zacks Equity Research

                    Teva (TEVA) Q2 Earnings Beat, Revenues Miss, Stock Down

                    by Zacks Equity Research

                    Teva's (TEVA) shares dip on mixed second-quarter results. The company maintains its 2018 sales guidance while raising the earnings outlook.

                      Zacks Equity Research

                      Company News For Aug 3, 2018

                      by Zacks Equity Research

                      Companies in the news are: CI, TSLA, TEVA and REGN

                        Zacks Equity Research

                        Teva (TEVA) Beats on Q2 Earnings, Misses Sales, Shares Dip

                        by Zacks Equity Research

                        Teva's (TEVA) second-quarter earnings beat estimates but sales miss expectations. Teva maintains its 2018 sales guidance while raising the earnings outlook. Shares dip in pre-market trading

                          Zacks Equity Research

                          Teva (TEVA) Q2 Earnings Coming Up: What's in the Cards?

                          by Zacks Equity Research

                          While pricing erosion in U.S. generics market and lower sales of Copaxone are expected to hurt sales at Teva (TEVA), cost savings from an aggressive restructuring plan will support the bottom line.

                            Zacks Equity Research

                            Dr. Reddy's (RDY) Earnings and Revenues Improve Y/Y in Q1

                            by Zacks Equity Research

                            Dr Reddy's (RDY) surpasses both earnings and sales year over year in the first quarter of fiscal 2019.

                              Zacks Equity Research

                              Amgen (AMGN) Q2 Earnings & Sales Beat Estimates, View Up

                              by Zacks Equity Research

                              Amgen (AMGN) impresses with better-than-estimated second-quarter results and raises its outlook for the full year. Shares rise in after-hours trading.

                                Zacks Equity Research

                                Pfizer & Lilly's Pain Candidate Succeeds in Phase III Study

                                by Zacks Equity Research

                                Pfizer (PFE) and Eli Lilly (LLY) announce that their investigational pain candidate, tanezumab, significantly reduces pain in osteoarthritis patients.

                                  Tirthankar Chakraborty headshot

                                  4 Warren Buffett Stocks to Buy in Q2 Earnings

                                  by Tirthankar Chakraborty

                                  We highlight four of the Oracle of Omaha's sought-after companies that are likely to report upbeat second-quarter earnings.

                                    Zacks Equity Research

                                    Has Teva Pharmaceutical Industries (TEVA) Outpaced Other Medical Stocks This Year?

                                    by Zacks Equity Research

                                    Is (TEVA) Outperforming Other Medical Stocks This Year?

                                      Zacks Equity Research

                                      TEVA or AKRX: Which Is the Better Value Stock Right Now?

                                      by Zacks Equity Research

                                      TEVA vs. AKRX: Which Stock Is the Better Value Option?

                                        Zacks Equity Research

                                        Lilly Wins Favorable Ruling From U.S. Court in Alimta Row

                                        by Zacks Equity Research

                                        Lilly (LLY) gets a favorable ruling from a U.S. district court in a patent related dispute against Dr. Reddy's Laboratories, concerning its key cancer drug Alimta's vitamin regimen patent.

                                          Zacks Equity Research

                                          Teva to Discontinue a Fremanezumab Study on Cluster Headache

                                          by Zacks Equity Research

                                          Teva decides to halt a phase III study, evaluating fremanezumab for the treatment of chronic cluster headache, following an interim analysis, which anticipates that the study is unlikely to meet its endpoint.

                                            Zacks Equity Research

                                            Mylan (MYL) to Get CRL Again for Generic Advair from FDA

                                            by Zacks Equity Research

                                            Mylan (MYL) suffers another setback with its ANDA for Advair as the FDA refuses to approve the same, due to minor deficiencies.

                                              Zacks Equity Research

                                              Abbvie/Roche's Leukemia Drugs Combination Gets FDA Approval

                                              by Zacks Equity Research

                                              AbbVie (ABBV) and Roche's (RHHBY) cancer drugs, Venclexta and Rituxan receive approval for combination use in second-line chronic lymphocytic leukemia.

                                                Zacks Equity Research

                                                Nektar (NKTR) Seeks Approval for Analgesic Opioid Candidate

                                                by Zacks Equity Research

                                                Nektar (NKTR) submits NDA to the FDA seeking approval of its analgesic opioid candidate, NKTR-181, for the treatment of chronic low back pain.

                                                  Zacks Equity Research

                                                  Teva (TEVA) Stock Up 17% YTD After a Dismal 2017: Here's Why

                                                  by Zacks Equity Research

                                                  Teva's (TEVA) shares gain 17% in 2018 so far after declining sharply in 2017.